Unilife Corp. (NASDAQ:UNIS)

CAPS Rating: 1 out of 5

Results 1 - 16 of 16

Recs

0
Member Avatar dalemx (< 20) Submitted: 4/29/2014 3:20:07 PM : Underperform Start Price: $3.14 UNIS Score: +32.95

This one is ripe for BR.

Recs

0
Member Avatar drabed1 (< 20) Submitted: 5/23/2013 5:32:24 PM : Outperform Start Price: $3.85 UNIS Score: -61.56

as a doctor the use for these material will increase due to focus on health of employee to deliver drug all injectable medication can end up being given this way

Recs

0
Member Avatar WakeUpInvestor (23.17) Submitted: 2/1/2013 4:48:27 PM : Outperform Start Price: $2.39 UNIS Score: -36.48

turnaround play but everything is on track

Recs

1
Member Avatar Tyrone85 (94.68) Submitted: 1/11/2013 8:50:27 PM : Outperform Start Price: $2.33 UNIS Score: -37.10

$7.70 or more

Recs

0
Member Avatar allanmsmith (< 20) Submitted: 10/31/2012 5:29:09 PM : Outperform Start Price: $2.70 UNIS Score: -55.39

Unilife makes a patented prefilled syringe with safety features to eliminate the risk of infection from needlestick injuries. Unilife and Sanofi-Aventis have entered into an exclusive five year agreement for the Unifill ready-to-fill syringes. Sanofi-aventis is developing applications in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.Unilife is speculative stock with interesting prospects for growth or as a takeover target

Recs

0
Member Avatar 4114McN (< 20) Submitted: 3/30/2012 3:06:24 PM : Outperform Start Price: $4.10 UNIS Score: -85.55

Late 2012 through 2013 is the earliest I would expect any significant earnings.

Recs

0
Member Avatar BuffettJunior1 (96.94) Submitted: 10/16/2011 7:19:34 PM : Underperform Start Price: $5.04 UNIS Score: +119.13

I am shocked at how overvalued this company is. Those of you who invested in this, did you even glance at the financial statements? Please somebody explain to me how a terrible company like this can have such a high valuation.

Recs

2
Member Avatar Lcrazylegs84 (< 20) Submitted: 9/14/2011 9:53:24 PM : Outperform Start Price: $4.48 UNIS Score: -114.02

Has the right managment and the right product to make an inpression on its sector.

Recs

0
Member Avatar EclecticRecluse (79.62) Submitted: 3/18/2011 3:58:46 AM : Underperform Start Price: $4.78 UNIS Score: +106.73

Extremely High Price for Book Value

Recs

0
Member Avatar Scottie31 (99.39) Submitted: 7/18/2010 8:26:46 PM : Outperform Start Price: $5.50 UNIS Score: -144.54

Good spec pick. Looking for a rebound on the price after the recent decline.

Recs

1
Member Avatar shaynes222 (< 20) Submitted: 5/23/2010 8:56:25 AM : Outperform Start Price: $5.65 UNIS Score: -143.13

New mfg facility coming online in 2011. Safety device gives this syringe product an edge and has regulatory trending toward requiring these safety features in US and Europe.

Recs

5
Member Avatar ChrisGraley (29.72) Submitted: 4/20/2010 8:50:33 PM : Outperform Start Price: $7.75 UNIS Score: -135.27

This is a speculative play that may jump around more than a long-tailed cat in a room full of rocking chairs.

Their claim to fame is a pre-filled syringe that is impossible to use a second time. This doesn't sound like much, but it's key to preventing AIDs and hepatitis in 3rd world countries.

An exclusive agreement with Sanofi Aventis is the closest thing that you have to a moat here, but that gives them 40% of the pre-filled syringe market.

Being first to market with a niche product should allow them to gain more short term market share.

The key is how quickly that they can lock up exclusive deals. If they can dry up the market before someone else figures out how to duplicate their product, they'll be sitting pretty.

Those of you that like to follow me into the pool should do your own DD because this is a very risky pick.

Recs

0
Member Avatar kpdobe (63.65) Submitted: 4/20/2010 5:11:24 PM : Outperform Start Price: $7.75 UNIS Score: -135.27

Just got a major account. Market is supposed to be tremendous for this product.

Recs

0
Member Avatar jdn74 (< 20) Submitted: 3/17/2010 10:03:44 AM : Outperform Start Price: $6.56 UNIS Score: -135.55

Unilife has a unique, disruptive technology that (in terms of safety devices) is required for use under US law, and likely to become required by law in the EU and other countries. They have the backing of one of the largest pharmaceutical companies in the world (sanofi-Aventis) and they are just getting started. Manufacturing of their first type of syringe just started this year and they are in the process of securing licensing agreements worldwide. They have numerous other safety syringes in the pipeline.

Great company. Necessary product. Zero (or far inferior) competition.

Recs

0
Member Avatar thedogsmad (92.25) Submitted: 3/4/2010 4:18:35 PM : Outperform Start Price: $7.40 UNIS Score: -144.89

this has buyout written all over it at this price, but i have to wait -- Sanofi figured that too, they have a clause in the contract to match any offer for a few years (and they GAVE them the money to build their plant)

Recs

0
Member Avatar PapiShasho (< 20) Submitted: 3/3/2010 12:19:44 PM : Outperform Start Price: $7.95 UNIS Score: -147.95

This is so insanely underpriced, along with so much potential, that it's a no-brainer. The recently finalized deal with Sanofi-Aventis only confirms a very bright future for this company and it's ingenious product.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement